Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-G28 in Lactose Intolerance
NCT02673749Phase 3Completed
- Sponsor
- Ritter Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Oct 2016
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of galacto-oligosaccharides in lactose intolerance (3 arms), sponsored by Ritter Pharmaceuticals. Primary endpoint: Change from baseline in abdominal pain at Day 31. Started Feb 2016; status: completed.
02
Drugs
galacto-oligosaccharides
03
Conditions
lactose intolerance
Beyond the preview
Go deeper on NCT02673749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673749.